Webinar

The Changing Landscape and Advances in the Treatment of Multiple Myeloma (APAC)

We will outline the overview of the current treatments available for multiple myeloma including the loss of market exclusivity for key products in the space. We will also discuss the latest research and innovations that are driving new treatments to help improve patient outcomes in multiple myeloma, including the debate over the risk of secondary malignancies from cell therapy.

Speakers

Sam Fazeli

Head of EMEA Research

Bloomberg

Sam Fazeli is a senior analyst and the EMEA head of Bloomberg Intelligence, a dynamic platform for in-depth research available on the Bloomberg Professional service at BI . Dr. Fazeli specializes in global pharmaceuticals, bringing over 20 years of experience conducting equity research as a pharmaceutical analyst, working at firms such as Nomura International and HSBC. Prior to joining Bloomberg in 2010, Dr. Fazeli worked at Piper Jaffray, Ltd. as a pharmaceutical analyst and head of European research. Before transitioning to investment banking, he was a research scientist for seven years. Dr. Fazeli has been ranked a top analyst by both the U.K. and Pan-European Extel surveys. He received a bachelor’s of science from Cardiff University, and a Ph.D. in pharmacology from the University of London.

Dr. Andrew Yee

Clinical Director, Center for Multiple Myeloma

Massachusetts General Hospital, Education Center

Andrew Yee, MD, is an Assistant Professor of Medicine at Harvard Medical School (07/2007 - Present) and is Clinical Director at the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center (07/2007 - Present) His clinical and research focus is multiple myeloma and related conditions; he actively sees patients as their primary oncologist or consultant. He is the principal investigator of several trials for patients with relapsed multiple myeloma.

Register

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Access a broad range of analysis, research, insight and actionable ideas with Bloomberg webinars.